# A Dose-Finding Study of Vedolizumab for Treatment of Steroid-Refractory Acute Intestinal Graft-Versus-Host Disease (GvHD) in Participants Who Have Undergone Allogeneic Hematopoietic Stem Cell Transplantation (Allo-HSCT)

> **NCT02993783** · PHASE2 · TERMINATED · sponsor: **Millennium Pharmaceuticals, Inc.** · enrollment: 17 (actual)

## Conditions studied

- Allogeneic Hematopoietic Stem Cell Transplantation

## Interventions

- **DRUG:** Vedolizumab

## Key facts

- **NCT ID:** NCT02993783
- **Lead sponsor:** Millennium Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-04-28
- **Primary completion:** 2018-05-09
- **Final completion:** 2018-05-09
- **Target enrollment:** 17 (ACTUAL)
- **Why stopped:** Lack of efficacy of the drug; no safety concern
- **Last updated:** 2019-05-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02993783

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02993783, "A Dose-Finding Study of Vedolizumab for Treatment of Steroid-Refractory Acute Intestinal Graft-Versus-Host Disease (GvHD) in Participants Who Have Undergone Allogeneic Hematopoietic Stem Cell Transplantation (Allo-HSCT)". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT02993783. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*